[Chemotherapy of bronchogenic cancer (author's transl)].
This report summarizes our experience with protocols "ACLI" and with alternative combinations such as ifosfamide plus etoposide in the chemotherapy of inoperable bronchogenic carcinoma. Using the "ACO"-protocols and consolidating irradiation, 77% complete remissions were achieved in patients with limited disease (median survival of 21 months). Patients with extensive disease (50% complete remissions) had a median survival of 10 months. The survival data point to a plateau after 30 months, suggesting that approximately 20% of limited disease patients may achieve long-term survival. Relapse patterns are analyzed.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents
Chemotherapie and palliative therapie des bronchialcarcinoms.